A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Completed · Phase 2

Conditions studied: Chronic Hepatitis C

In brief

A Phase 2 study to evaluate the safety and efficacy of two different once daily doses VX-135 in combination with ribavirin in treatment-naïve subjects with chronic hepatitis C

Key facts

Study ID

NCT01726946

Run by

Vertex Pharmaceuticals Incorporated

People needed

10

Starts

2012-11-01

Expected to finish

2014-02-01

Last updated by the study team

2015-04-16

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

Where it is running

• California — La Jolla, California, United States
• Florida — Orlando, Florida, United States
• Georgia — Marietta, Georgia, United States
• Tennessee — Germantown, Tennessee, United States
• Texas — Arlington, Texas, United States
• Texas — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.